Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H30O2 |
| Molecular Weight | 290.4403 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC=C4C[C@@H](O)CC[C@]34C
InChI
InChIKey=QADHLRWLCPCEKT-LOVVWNRFSA-N
InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB01524
http://www.webmd.com/vitamins-supplements/ingredientmono-595-androstenediol.aspx?activeingredientid=595&activeingredientname=androstenediol
Curator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB01524
http://www.webmd.com/vitamins-supplements/ingredientmono-595-androstenediol.aspx?activeingredientid=595&activeingredientname=androstenediol
This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. The value of Δ5-diol as a radiation countermeasure is based mainly on its stimulation of production of white blood cells and platelets. Androstenediol used by the body to make testosterone and estrogen. There is some concern that androstenediol might increase the risk of coronary heart disease. There is also developing evidence that androstenediol might help prostate cancer cells grow. Taking androstenediol along with estrogen and testosterone pills might cause too much estrogen or testosterone in the body.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of testosterone precursor supplementation on intensive weight training. | 2001 Apr |
|
| cyp7b1 catalyses the 7alpha-hydroxylation of dehydroepiandrosterone and 25-hydroxycholesterol in rat prostate. | 2001 Apr 15 |
|
| Non-steroidal and steroidal sulfamates: new drugs for cancer therapy. | 2001 Jan 22 |
|
| In vivo protection against gamma-irradiation with 5-androstenediol. | 2001 Jul |
|
| Synthesis and steroid sulphatase inhibitory activity of C19- and C21-steroidal derivatives bearing a benzyl-inhibiting group. | 2001 Jul-Aug |
|
| Serum concentration of androstenediol and androstenediol sulfate in patients with hyperthyroidism and hypothyroidism. | 2001 Jun |
|
| Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). | 2001 Jun |
|
| Influence of estrogens on the androgen metabolism in different subunits of human hair follicles. | 2001 May-Jun |
|
| Hormonal steroidogenesis in liver and small intestine of the green frog, Rana esculenta L. | 2001 Nov 2 |
|
| Endocrine and lipid responses to chronic androstenediol-herbal supplementation in 30 to 58 year old men. | 2001 Oct |
|
| In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system. | 2001 Sep |
|
| Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. | 2002 Aug |
|
| Dehydroepiandrosterone (DHEA) metabolism in Saccharomyces cerevisiae expressing mammalian steroid hydroxylase CYP7B: Ayr1p and Fox2p display 17beta-hydroxysteroid dehydrogenase activity. | 2002 Jul |
|
| Serum sex hormones and breast cancer risk factors in postmenopausal women. | 2003 Apr |
|
| 3Beta-sulfamate derivatives of C19 and C21 steroids bearing a t-butylbenzyl or a benzyl group: synthesis and evaluation as non-estrogenic and non-androgenic steroid sulfatase inhibitors. | 2003 Feb |
|
| Oral andro-related prohormone supplementation: do the potential risks outweigh the benefits? | 2003 Feb |
|
| Chronic effects of dehydroepiandrosterone on rat adipose tissue metabolism. | 2003 Mar |
|
| Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. | 2003 Oct |
|
| Steroid sulphatase inhibitors for breast cancer therapy. | 2003 Sep |
|
| Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol. | 2004 Aug |
|
| Anabolic-androgenic steroids and testosterone precursors: ergogenic aids and sport. | 2004 Aug |
|
| Analysis of the nutritional supplement 1AD, its metabolites, and related endogenous hormones in biological matrices using liquid chromatography-tandem mass spectrometry. | 2004 Jan-Feb |
|
| Analytical strategies for the detection of non-labelled anabolic androgenic steroids in nutritional supplements. | 2004 Jul |
|
| Virilization of young children after topical androgen use by their parents. | 2004 Jul |
|
| Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF. | 2005 |
|
| C(19)-5-ene steroids in nature. | 2005 |
|
| Mechanism of salutary effects of androstenediol on hepatic function after trauma-hemorrhage: role of endothelial and inducible nitric oxide synthase. | 2005 Feb |
|
| Application of stable carbon isotope analysis to the detection of 17beta-estradiol administration to cattle. | 2005 Nov 4 |
|
| Circulating neuroactive C21- and C19-steroids in young men before and after ejaculation. | 2006 |
|
| Arginine 276 controls the directional preference of AKR1C9 (rat liver 3alpha-hydroxysteroid dehydrogenase) in human embryonic kidney 293 cells. | 2006 Apr |
|
| Androstenediol administration after trauma-hemorrhage attenuates inflammatory response, reduces organ damage, and improves survival following sepsis. | 2006 Aug |
|
| Modulation of neurosteroid production in human neuroblastoma cells by Alzheimer's disease key proteins. | 2006 Jul |
|
| Metabolism of steroid hormones by Taenia solium and Taenia crassiceps cysticerci. | 2006 Jun |
|
| Sex steroid concentrations and localization of steroidogenic enzyme expression in free-ranging female northern fur seals (Callorhinus ursinus). | 2006 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: In Phase I human safety studies conducted in the U.S. and The Netherlands, as of December 2005, a total of 111 volunteers had been enrolled, with 39 volunteers having completed the 5-day treatment course.
The 200 mg dose given over 5 days may be effective as a radiation countermeasure for humans
Route of Administration:
Intramuscular
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2360
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
||
|
LOINC |
55851-0
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
||
|
LOINC |
25314-6
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
||
|
LOINC |
34238-6
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
||
|
LOINC |
34237-8
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
||
|
LOINC |
56033-4
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
||
|
LOINC |
34236-0
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C95979
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
208-306-8
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
95PS51EMXY
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
521-17-5
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
214
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
Androstenediol
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
12163
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
2710
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
DTXSID9022609
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
D015114
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL440283
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
m1900
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000077399
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
SUB12899MIG
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
10634
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY | |||
|
DB01524
Created by
admin on Fri Dec 15 15:00:28 GMT 2023 , Edited by admin on Fri Dec 15 15:00:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE)
